Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Clinical Presentation and Management of Valley Fever

Introduction to Valley Fever

  • Valley fever typically presents as a self-limited acute or subacute community-acquired pneumonia that becomes evident 1-3 weeks after infection with Coccidioides fungi, according to Praxis Medical Insights 1

Common Clinical Manifestations

  • The most frequently reported symptoms include fever, fatigue, chills, and myalgia, as reported by MMWR Recommendations and Reports 2
  • Severe, debilitating headaches are common and may be retroorbital with photophobia, sometimes misdiagnosed as migraines or dental issues, according to MMWR Recommendations and Reports 2
  • Respiratory symptoms include pneumonia with cough and chest pain, as noted by MMWR Recommendations and Reports and Praxis Medical Insights 2, 3

Disease Course and Progression

  • Symptoms typically appear 1-3 weeks after exposure to the fungal spores, according to Praxis Medical Insights 1
  • Fever typically lasts a median of 10 days in untreated patients and usually resolves within 72 hours of appropriate treatment, as reported by MMWR Recommendations and Reports 2
  • Systemic symptoms improve first, followed by respiratory symptoms, with fatigue often being the most persistent symptom, according to Clinical Infectious Diseases 4
  • In immunocompetent individuals, most infections are self-limited and resolve spontaneously without specific antifungal therapy, as noted by Praxis Medical Insights 3, 5

Diagnostic Considerations

  • Serologic testing is the primary diagnostic method, including both IgM and IgG antibodies against coccidioidal antigens, according to Praxis Medical Insights 3
  • Erythrocyte sedimentation rate is often elevated and can be used to monitor improvement, as reported by Clinical Infectious Diseases 4

Treatment Approach

  • For immunocompetent patients with mild to moderate symptoms, antifungal therapy is generally not required, according to Praxis Medical Insights 3, 5
  • Antifungal treatment is indicated for severe primary pulmonary disease, patients with risk factors for dissemination, and disseminated disease, as noted by Praxis Medical Insights 3, 5
  • Fluconazole is the standard first-line drug, with a dosage of 400 mg daily for mild-moderate disease and 800 mg daily for severe disease, according to Praxis Medical Insights 3, 5

Follow-up and Monitoring

  • Regular medical follow-up is essential for all patients with valley fever, as reported by Clinical Infectious Diseases 4
  • Laboratory studies and chest radiographs should be monitored periodically to assess disease resolution, according to Clinical Infectious Diseases 4

Common Pitfalls

  • Misdiagnosis as bacterial pneumonia or other respiratory infections due to similar presentation, as noted by MMWR Recommendations and Reports 2
  • Unnecessary antifungal treatment in immunocompetent patients with mild disease can lead to adverse effects without clinical benefit, according to Praxis Medical Insights 5
  • Failure to consider valley fever in patients with compatible symptoms who have lived in or traveled to endemic regions, as reported by Praxis Medical Insights 1

REFERENCES

1

Valley Fever: Cause, Pathophysiology, and Epidemiology [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Diagnostic Approach and Treatment for Valley Fever [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

Treatment for Valley Fever (Coccidioidomycosis) [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025